$リペア・セラピューティクス(RPTX.US)$ NEWS Repare Therapeutics & Debiopharm Announce First Patient Dosed in Phase 1/1b MYTHIC Trial Evaluating the Synthetic Lethal Combination of PKMYT1 and WEE1 Inhibition The collaboration between Repare Therapeutics and Debiopharm to evaluate the combination of lunresertib and Debio 0123 shows promise for cancer patients with high unmet medical needs. The first patient dosed in the Phase 1/1b MYTHIC trial is a significant milestone, allowing for the swift execution o...
$リペア・セラピューティクス(RPTX.US)$Especially the MINOTAUR phase 1 Data release soon? 2024 Outlook: •Initiate a Phase 1/1b clinical trial of lunresertib and Debio 0123, a WEE1 inhibitor, in the first half of 2024 as a fourth arm of the ongoing MYTHIC clinical trial. •Report initial ...
Repare Therapeutics' low P/S ratio is likely due to poor revenue performance and negative growth forecasts. The company's poor outlook compared to other industry players justifies its low P/S ratio.
The company's falling revenue and high cash burn relative to its market value are concerning. Despite a promising cash runway, the cash burn situation is considered a bit risky and causes some nervousness about the stock.
Repare Therapeutics' shrinking revenues and declining revenue forecast could challenge its P/S maintenance, possibly hindering significant share price growth. Its low P/S is acceptable to shareholders considering future revenue stagnation.
$リペア・セラピューティクス(RPTX.US)$Repare Therapeutics Announces Positive Initial Data from Phase 1 MYTHIC Clinical Trial Evaluating Lunresertib Alone and in Combination with Camonsertib
RDK79 :
Another useless news posting this morning by investorobserver pinging for app downloads and subscribers, while just trolling with useless news headline. Download the app Stock Price data may be delayed up to 15 minutes. Copyright 2022. Portions of this content may be copyrighted by Fresh Brewed Media, Investors Observer, and/or O2 Media LLC. All Rights Reserved. Portions of this content protected by US Patent numbers 7,865,496, 7,856,390, and 7,716,116. Investing in stocks, bonds, option and other financial instruments involve risks and may not be suitable for everyone. Portfolio results are unaudited and based on varying investment expiration dates. Terms of Service | Privacy Policy
Bawlz09 :
not being rude in saying this. but lol pre market mover . 3% down side... is a $2 stock lol? and I know u didn't pick this. I was just laughing .. @ $Airspan Networks (MIMO.US)$ being a pre market mover chart. on 3% lol... btw they went from -$20 a share to +$0.20 a share in just over a year. and Gaines 50% ish rev I think. so they went from a $20 stock to like 2 dollars .. might be worth looking at now. idk tho. haven't looked at balance sheet yet.
リペア・セラピューティクスに関するコメント
NEWS
Repare Therapeutics & Debiopharm Announce First Patient Dosed in Phase 1/1b MYTHIC Trial Evaluating the Synthetic Lethal Combination of PKMYT1 and WEE1 Inhibition
The collaboration between Repare Therapeutics and Debiopharm to evaluate the combination of lunresertib and Debio 0123 shows promise for cancer patients with high unmet medical needs.
The first patient dosed in the Phase 1/1b MYTHIC trial is a significant milestone, allowing for the swift execution o...
Some dates to watch for!
•Initiate a Phase 1/1b clinical trial of lunresertib and Debio 0123, a WEE1 inhibitor, in the first half of 2024 as a fourth arm of the ongoing MYTHIC clinical trial. •Report initial ...
コラムToday's pre-market stock movers: CHWY, PATH, SNAP, HPE and more
• $リペア・セラピューティクス(RPTX.US)$ +26.4% (announces worldwide license and collaboration agreement with Roche for camonsertib)
• $チューイー(CHWY.US)$+19.8% (Chewy stock soars on earnings. Here's what really mattered)
• $ユーアイパス(PATH.US)$ +11.7% ( reported first-quarter revenue growth of 32% year-over-year to $245.1 million)
• $ピュア・ストレージ(PSTG.US)$ +10.6% (In reaction to earnings)
• $クレド・テクノロジー・グループ・ホールディング(CRDO.US)$ +10.2% (In reaction ...
コラムToday's pre-market stock movers: CRWD, CAH, DPZ, CSCO and more
• $アクチニウム・ファーマシューティカルズ(ATNM.US)$ +30.81% (Actinum Pharma and Immedica to commercialize lomab-B (1311 apamistamab) in Europe the Middle East and North Africa)
• $Aeglea BioTherapeutics(AGLE.US)$ +18.11% (presents additional data from PEACE phase 3 study of Pegzilarginase; submits BLA to FDA for Pegzilarginase)
• $グリッド・ダイナミクス・ホールディングス(GDYN.US)$ +5% (expands in Europe ceases operations in Russia)
• $アーチザン・パートナーズ・アセットマネジメント(APAM.US)$ +4....
コラムARK latest trades
$テラドック・ヘルス(TDOC.US)$$リペア・セラピューティクス(RPTX.US)$$ROCHE HOLDING AG(RHHBY.US)$$リジェネロン・ファーマシューティカルズ(REGN.US)$$ノバルティス(NVS.US)$$ズーム・ビデオ・コミュニケーションズ(ZM.US)$$テスラ(TSLA.US)$
コラムArk lastest trades
$アリババ・グループ・ホールディング(BABA.US)$$テンセント(TCEHY.US)$$インタラクティブ・ブローカーズ・グループ(IBKR.US)$$テラドック・ヘルス(TDOC.US)$$武田薬品工業(TAK.US)$$サーフェイス・オンコロジー(SURF.US)$$リペア・セラピューティクス(RPTX.US)$$ROCHE HOLDING AG(RHHBY.US)$$リジェネロン・ファーマシューティカルズ(REGN.US)$$ノバルティス(NVS.US)$
まだコメントはありません